5:07 PM
 | 
Sep 11, 2017
 |  BC Extra  |  Clinical News

AbbVie's upadacitinib meets in second Phase III for RA

AbbVie Inc. (NYSE: ABBV) said both doses of oral upadacitinib (ABT-494) met the two primary endpoints in the Phase III SELECT-BEYOND trial to treat moderate to severe rheumatoid arthritis. Upadacitinib is an oral Janus kinase-1 (JAK-1) inhibitor.

On the first primary endpoint, a significantly greater proportion of patients who received once-daily 15 and 30 mg doses of upadacitinib achieved a 20% improvement in the American College of Rheumatology criteria (ACR20) at week 12 vs. placebo (65% and 56%, respectively, vs. 28%, p<0.001 for both). On the second primary endpoint, a significantly greater proportion of patients receiving low-...

Read the full 478 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >